SYS6063
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 03, 2026
CSPC PHARMA…announced that its first mRNA-LNP-based dual-target chimeric antigen receptor T-cell injection (SYS6063 injection) developed by the group has been approved by the National Medical Products Administration of China to conduct clinical trials in China.
(iis.aastocks.com)
- "The approved clinical indication is relapsed and refractory systemic lupus erythematosus."
New trial • Systemic Lupus Erythematosus
1 to 1
Of
1
Go to page
1